[Expression of CD44 in Tumor Tissue and Serum of Small Cell Lung Cancer and Its Clinical Prognostic Significance]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2021 Jun 30

PMID 34187156

Citations 4

Authors

Ying Wang

Yi Guo

Haifeng Lin

Lina Zhang

Hongmei Zhang

Qunhui Wang

Fanbin Hu

Jie Li

Baolan Li

Tongmei Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Small cell lung cancer (SCLC) is a highly aggressive malignancy characterized by rapid growth, early metastasis and acquired therapeutic resistance, and the prognosis is extremely poor. Studies have proved that the stem cell marker CD44 is correlated with tumor recurrence and treatment resistance, however, there are limited reports yet concerning on the CD44 expression and its clinical prognostic significance in SCLC patients. The purpose of this study is to investigate the expression of CD44 in tumor tissues as well as serum of SCLC patients and explore its correlation with the clinical characteristics, therapeutic effect and prognosis.

Methods: The tumor tissues and serum samples of 47 newly diagnosed SCLC patients were collected. Immunohistochemistry and enzyme-linked immunosorbent assay were applied to detect CD44. The relationship between CD44 level and the clinical characteristics as well as prognosis of the patients was analyzed.

Results: The stem cell marker CD44 was detectable both in serum sample and tumor tissue of SCLC patients. The positive rate of CD44 in tumor tissue was significantly higher in patients with performance status (PS) 2 than that of patients with PS 0-1 (85.71% vs 30%, P=0.017). Patients were divided in to different groups according to the treatment efficacy. The CD44 immunohistochemical score and serum level in the disease progression group were significantly higher than those in the disease control group, and the differences were statistically significant (P=0.006, P=0.034), Univariate analysis depicted that the progression-free survival (PFS) of CD44 positive patients was significantly shorter than that of CD44 negative patients (5.23 mon vs 9.03 mon, P=0.036).

Conclusions: The positive expression of CD44 in tumor tissues of pre-treatment SCLC patients is correlated with poor PFS. The clinical significance of CD44 is worthy to be further studied.

Citing Articles

CD44 and its implication in neoplastic diseases.

Xu Y, Bai Z, Lan T, Fu C, Cheng P MedComm (2020). 2024; 5(6):e554.

PMID: 38783892 PMC: 11112461. DOI: 10.1002/mco2.554.

Highly Sensitive Zinc Oxide Fiber-Optic Biosensor for the Detection of CD44 Protein.

Paltusheva Z, Ashikbayeva Z, Tosi D, Gritsenko L Biosensors (Basel). 2022; 12(11).

PMID: 36421133 PMC: 9688241. DOI: 10.3390/bios12111015.

Exploration and validation of hub genes in lung adenocarcinoma based on bioinformatics analysis.

Zeng C, Zhou Y, Ye W, Fang Z, Wang K Transl Cancer Res. 2022; 11(10):3814-3826.

PMID: 36388051 PMC: 9641136. DOI: 10.21037/tcr-22-2225.

Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts.

Furumoto H, Kato T, Wakiyama H, Furusawa A, Choyke P, Kobayashi H Biomedicines. 2022; 10(4).

PMID: 35453596 PMC: 9027987. DOI: 10.3390/biomedicines10040846.

References

Gkika E, Benndorf M, Oerther B, Mohammad F, Beitinger S, Adebahr S . Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer. Front Oncol. 2020; 10:1161. PMC: 7438800. DOI: 10.3389/fonc.2020.01161. View

Nguyen V, Mirejovsky T, Melinova L, Mandys V . CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma. 2001; 47(6):400-8. View

Si D, Yin F, Peng J, Zhang G . High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas. Cancer Manag Res. 2020; 12:769-775. PMC: 7006859. DOI: 10.2147/CMAR.S233423. View

Suda K, Murakami I, Yu H, Kim J, Tan A, Mizuuchi H . CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Mol Cancer Ther. 2018; 17(10):2257-2265. DOI: 10.1158/1535-7163.MCT-17-1279. View

Sawant S, Ahire C, Dongre H, Joshi S, Jamghare S, Rane P . Prognostic significance of elevated serum CD44 levels in patients with oral squamous cell carcinoma. J Oral Pathol Med. 2018; 47(7):665-673. DOI: 10.1111/jop.12731. View

Song J, Im J, Nho R, Han Y, Upadhyaya P, Kassie F . Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells. Mol Carcinog. 2018; 58(3):321-333. PMC: 11005861. DOI: 10.1002/mc.22930. View

Wang Y, Zou S, Zhao Z, Liu P, Ke C, Xu S . New insights into small-cell lung cancer development and therapy. Cell Biol Int. 2020; 44(8):1564-1576. PMC: 7496722. DOI: 10.1002/cbin.11359. View

Luo Z, Wu R, Lv L, Li P, Zhang L, Hao Q . Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol. 2014; 7(7):3632-46. PMC: 4128975. View

Liu Y, Wu T, Lu D, Zhen J, Zhang L . CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer. Int J Biol Markers. 2018; 33(3):308-313. DOI: 10.1177/1724600817746951. View

10.

Quan Y, Lim J, Choi B, Choi Y, Choi Y, Park J . Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2018; 83(3):399-410. DOI: 10.1007/s00280-018-3737-y. View

11.

Chaffer C, Goetz J . CD44 Orchestrates Metastatic Teamwork. Dev Cell. 2018; 47(6):691-693. DOI: 10.1016/j.devcel.2018.11.038. View

12.

Ko Y, Won H, Jeon E, Hong S, Roh S, Hong Y . Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer. 2011; 11:340. PMC: 3164633. DOI: 10.1186/1471-2407-11-340. View

13.

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

14.

Zhang C, Wang H, Wang X, Zhao C, Wang H . CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma. Cancer Cell Int. 2020; 20(1):583. PMC: 7720536. DOI: 10.1186/s12935-020-01671-4. View

15.

Takigawa N, Segawa Y, Mandai K, Takata I, Fujimoto N . Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features. Lung Cancer. 1997; 18(2):147-57. DOI: 10.1016/s0169-5002(97)00060-3. View

16.

Yeh C, Wu A, Chang P, Chen K, Yang C, Yang S . Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med. 2012; 186(11):1180-8. DOI: 10.1164/rccm.201207-1180OC. View

17.

Shinohara S, Hanagiri T, Taira A, Takenaka M, Oka S, Chikaishi Y . Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer. Oncology. 2016; 90(6):327-38. DOI: 10.1159/000445951. View

18.

Codony-Servat J, Verlicchi A, Rosell R . Cancer stem cells in small cell lung cancer. Transl Lung Cancer Res. 2016; 5(1):16-25. PMC: 4758966. DOI: 10.3978/j.issn.2218-6751.2016.01.01. View

19.

Batlle E, Clevers H . Cancer stem cells revisited. Nat Med. 2017; 23(10):1124-1134. DOI: 10.1038/nm.4409. View

20.

Zhao P, Damerow M, Stern P, Liu A, Sweet-Cordero A, Siziopikou K . CD44 promotes Kras-dependent lung adenocarcinoma. Oncogene. 2012; 32(43):5186-90. PMC: 4227610. DOI: 10.1038/onc.2012.542. View